The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Prognostic biomarkers and predictors of outcome in patients with neuroendocrine tumors
Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain, explores current prognostic biomarkers and predictors of outcome in patients with neuroendocrine tumors, highlighting factors such as proliferative index and primary tumor site as key indicators. Co-morbidities and other biological factors also play a role in prognosis, and some of these can be assessed using functional imaging. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
